The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2017

Filed:

Sep. 30, 2013
Applicant:

Ambit Biosciences Corporation, San Diego, CA (US);

Inventors:

Shinsuke Oba, Chuo-ku Tokyo, JP;

Hiroyasu Toyota, Chuo-ku Tokyo, JP;

Satomi Ikeuchi, Tokyo, JP;

Takumi Hara, Tokyo, JP;

Emiko Murayama, Tokyo, JP;

Kei Motonaga, Tokyo, JP;

Assignee:

Ambit Biosciences Corporation, San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/38 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01); A61K 47/40 (2006.01); A61K 31/5377 (2006.01); A61K 47/02 (2006.01); A61K 9/20 (2006.01); A61K 9/46 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0056 (2013.01); A61K 9/0007 (2013.01); A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 9/205 (2013.01); A61K 31/5377 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 47/40 (2013.01);
Abstract

Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-β-cyclodextrin in a ratio ranging from 1:8 to 1:20.


Find Patent Forward Citations

Loading…